NEW YORK, Feb 16 (Reuters) - Amgen Inc.'s multibillion-dollar anemia drug Aranesp is facing further safety concerns after a medical newsletter reported on Friday that a Danish study of the drug in ...
NEW YORK, Jan 26 (Reuters) - Amgen Inc. shares fell 5 percent on Friday after two of the company's medicines posted disappointing data, including a higher death rate for some cancer patients on its ...
The FDA previously updated the boxed warning for all erythropoiesis-stimulating agents (darbepoetin [Aranesp], epoetin alfa (Epogen, Procrit]) because of increased risk of serious and life-threatening ...
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women Two 16-week randomized, double-blind, placebo-controlled ...
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 Patients had a diagnosis of nonmyeloid malignancy with ≥ 8 weeks of planned chemotherapy, ...
Amgen Inc. has agreed to pay $762 million to resolve federal litigation accusing the drugmaker of marketing the anemia treatment Aranesp for unapproved uses. The Thousand Oaks, Calif., company pleaded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results